{"resourceType":"MedicinalProductDefinition","id":"drug-and-device","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: drug-and-device\u003c/p\u003e\u003cp\u003e\u003cb\u003eidentifier\u003c/b\u003e: id: Wonderdrug+\u003c/p\u003e\u003cp\u003e\u003cb\u003ecombinedPharmaceuticalDoseForm\u003c/b\u003e: \u003cspan\u003esolution for injection\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epackagedMedicinalProduct\u003c/b\u003e: \u003ca\u003e \u003c/a\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: package\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003epackage\u003c/b\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003econtainedItem\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eitem\u003c/b\u003e: \u003ca\u003e#liquidItem\u003c/a\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eamount\u003c/b\u003e: 20 ml\u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003econtainedItem\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eitem\u003c/b\u003e: \u003ca\u003e#syringeDevice\u003c/a\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003c/blockquote\u003e\u003c/blockquote\u003e\u003ch3\u003eNames\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eProductName\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eWonderdrug+ liquid 20ml\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/div\u003e"},"contained":[{"resourceType":"PackagedProductDefinition","id":"package","package":[{"containedItem":[{"item":[{"reference":"#liquidItem"}],"amountQuantity":{"value":20,"unit":"ml"}},{"item":[{"reference":"#syringeDevice"}]}]}]},{"resourceType":"DeviceDefinition","id":"syringeDevice","type":{"text":"syringe"}},{"resourceType":"ManufacturedItemDefinition","id":"liquidItem","manufacturedDoseForm":{"coding":[{"system":"http://example.org.uk/fhir/doseform","code":"solution for injection"}]},"ingredient":[{"reference":"#ingredient"}]},{"resourceType":"Ingredient","id":"ingredient","role":{"coding":[{"system":"http://example.org.uk/fhir/ingredientRole","code":"active"}]},"substance":{"codeCodeableConcept":{"coding":[{"system":"http://example.org.uk/fhir/ingredients","code":"12345","display":"Wondersubstance BP"}]}}}],"identifier":[{"system":"http://example.org.uk/fhir/product","value":"Wonderdrug+"}],"combinedPharmaceuticalDoseForm":{"coding":[{"system":"http://example.org.uk/fhir/doseform","code":"solution for injection"}]},"packagedMedicinalProduct":[{"reference":"#package"}],"name":[{"productName":"Wonderdrug+ liquid 20ml"}]}
{"resourceType":"MedicinalProductDefinition","id":"equilidem-basics","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: equilidem-basics\u003c/p\u003e\u003cp\u003e\u003cb\u003eidentifier\u003c/b\u003e: id: Equilidem25\u003c/p\u003e\u003cp\u003e\u003cb\u003ecombinedPharmaceuticalDoseForm\u003c/b\u003e: \u003cspan\u003etablet\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eindication\u003c/b\u003e: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class \u0026gt;\u003d II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.\u003c/p\u003e\u003cp\u003e\u003cb\u003elegalStatusOfSupply\u003c/b\u003e: \u003cspan\u003ePrescription only medicine\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eclassification\u003c/b\u003e: \u003cspan\u003eB01A\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eingredient\u003c/b\u003e: \u003c/p\u003e\u003cul\u003e\u003cli\u003e\u003cspan\u003eEquilidonium Phosphate\u003c/span\u003e\u003c/li\u003e\u003cli\u003e\u003cspan\u003eCalcium Carbonate\u003c/span\u003e\u003c/li\u003e\u003c/ul\u003e\u003ch3\u003eNames\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eProductName\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eEquilidem 2.5 mg film-coated tablets\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003ch3\u003eCrossReferences\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eProduct\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd/\u003e\u003c/tr\u003e\u003c/table\u003e\u003ch3\u003eManufacturingBusinessOperations\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eManufacturer\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003e\u003cspan\u003eEquiliDrugCo Inc.\u003c/span\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/div\u003e"},"identifier":[{"system":"http://example.org.uk/fhir/product","value":"Equilidem25"}],"combinedPharmaceuticalDoseForm":{"coding":[{"system":"http://example.org.uk/fhir/dosefom","code":"tablet"}]},"indication":"Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class \u003e\u003d II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.","legalStatusOfSupply":{"coding":[{"system":"http://example.org.uk/fhir/legalstatusofsupply","code":"POM","display":"Prescription only medicine"}]},"classification":[{"coding":[{"system":"http://www.whocc.no/atc/example","code":"B01A"}]}],"ingredient":[{"display":"Equilidonium Phosphate"},{"display":"Calcium Carbonate"}],"name":[{"productName":"Equilidem 2.5 mg film-coated tablets"}],"crossReference":[{"product":{"reference":{"reference":"MedicinalProductDefinition/genericEquilidonium"}}}],"manufacturingBusinessOperation":[{"manufacturer":[{"display":"EquiliDrugCo Inc."}]}]}
{"resourceType":"MedicinalProductDefinition","id":"equilidem-with-ing-and-auth","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: equilidem-with-ing-and-auth\u003c/p\u003e\u003cp\u003e\u003cb\u003eidentifier\u003c/b\u003e: id: Equilidem25\u003c/p\u003e\u003cp\u003e\u003cb\u003ecombinedPharmaceuticalDoseForm\u003c/b\u003e: \u003cspan\u003etablet\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eindication\u003c/b\u003e: Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class \u0026gt;\u003d II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.\u003c/p\u003e\u003cp\u003e\u003cb\u003elegalStatusOfSupply\u003c/b\u003e: \u003cspan\u003ePrescription only medicine\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eclassification\u003c/b\u003e: \u003cspan\u003eB01A\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eingredient\u003c/b\u003e: \u003c/p\u003e\u003cul\u003e\u003cli\u003e\u003ca\u003e \u003c/a\u003e\u003c/li\u003e\u003cli\u003e\u003ca\u003e \u003c/a\u003e\u003c/li\u003e\u003c/ul\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: EquilidoniumPhosphate\u003c/p\u003e\u003cp\u003e\u003cb\u003erole\u003c/b\u003e: \u003cspan\u003eactive\u003c/span\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003esubstance\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003ecode\u003c/b\u003e: \u003cspan\u003eEquilidonium Phosphate\u003c/span\u003e\u003c/p\u003e\u003ch3\u003eStrengths\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003ePresentation\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003e22 ml/1 tablet\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/blockquote\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: CalciumCarbonate\u003c/p\u003e\u003cp\u003e\u003cb\u003erole\u003c/b\u003e: \u003cspan\u003eexcipient\u003c/span\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003esubstance\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003ecode\u003c/b\u003e: \u003cspan\u003eCalcium Carbonate\u003c/span\u003e\u003c/p\u003e\u003ch3\u003eStrengths\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003ePresentation\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003e3 ml/1 tablet\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/blockquote\u003e\u003c/blockquote\u003e\u003ch3\u003eNames\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eProductName\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003eEquilidem 2.5 mg film-coated tablets\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003ch3\u003eCrossReferences\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eProduct\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd/\u003e\u003c/tr\u003e\u003c/table\u003e\u003ch3\u003eManufacturingBusinessOperations\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eManufacturer\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003e\u003cspan\u003eEquiliDrugCo Processing Inc.\u003c/span\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/div\u003e"},"contained":[{"resourceType":"Ingredient","id":"EquilidoniumPhosphate","role":{"coding":[{"system":"http://example.org.uk/fhir/ingredientType","code":"active"}]},"substance":{"codeCodeableConcept":{"coding":[{"system":"http://example.org.uk/fhir/substances","code":"123456","display":"Equilidonium Phosphate"}]},"strength":[{"presentation":{"numerator":{"value":22,"unit":"ml"},"denominator":{"value":1,"unit":"tablet"}}}]}},{"resourceType":"Ingredient","id":"CalciumCarbonate","role":{"coding":[{"system":"http://example.org.uk/fhir/ingredientType","code":"excipient"}]},"substance":{"codeCodeableConcept":{"coding":[{"system":"http://example.org.uk/fhir/substances","code":"456789","display":"Calcium Carbonate"}]},"strength":[{"presentation":{"numerator":{"value":3,"unit":"ml"},"denominator":{"value":1,"unit":"tablet"}}}]}}],"identifier":[{"system":"http://example.org.uk/fhir/product","value":"Equilidem25"}],"combinedPharmaceuticalDoseForm":{"coding":[{"system":"http://example.org.uk/fhir/dosefom","code":"tablet"}]},"indication":"Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class \u003e\u003d II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.","legalStatusOfSupply":{"coding":[{"system":"http://example.org.uk/fhir/legalstatusofsupply","code":"POM","display":"Prescription only medicine"}]},"classification":[{"coding":[{"system":"http://www.whocc.no/atc/example","code":"B01A"}]}],"ingredient":[{"reference":"#EquilidoniumPhosphate"},{"reference":"#CalciumCarbonate"}],"name":[{"productName":"Equilidem 2.5 mg film-coated tablets"}],"crossReference":[{"product":{"reference":{"reference":"MedicinalProductDefinition/genericEquilidonium"}}}],"manufacturingBusinessOperation":[{"manufacturer":[{"display":"EquiliDrugCo Processing Inc."}]}]}
{"resourceType":"MedicinalProductDefinition","id":"example","text":{"status":"generated","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eid\u003c/b\u003e: example\u003c/p\u003e\u003cp\u003e\u003cb\u003eidentifier\u003c/b\u003e: id: {mpid}\u003c/p\u003e\u003cp\u003e\u003cb\u003eclassification\u003c/b\u003e: \u003cspan\u003eB01AF02\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eattachedDocument\u003c/b\u003e: \u003ca\u003eGenerated Summary: id: example; id: urn:oid:1.3.6.1.4.1.21367.2005.3.7.1234; status: current; docStatus: preliminary; \u003cspan\u003eOutpatient Note\u003c/span\u003e; \u003cspan\u003eHistory and Physical\u003c/span\u003e; \u003cspan\u003eArm\u003c/span\u003e; \u003cspan\u003eOutpatient\u003c/span\u003e; \u003cspan\u003eGeneral Medicine\u003c/span\u003e; period: 23/12/2004 8:00:00 AM --\u0026gt; 23/12/2004 8:01:00 AM; date: 24/12/2005 9:43:41 AM; description: Physical; \u003cspan\u003every restricted\u003c/span\u003e\u003c/a\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003emasterFile\u003c/b\u003e: \u003ca\u003eGenerated Summary: id: example; id: urn:oid:1.3.6.1.4.1.21367.2005.3.7.1234; status: current; docStatus: preliminary; \u003cspan\u003eOutpatient Note\u003c/span\u003e; \u003cspan\u003eHistory and Physical\u003c/span\u003e; \u003cspan\u003eArm\u003c/span\u003e; \u003cspan\u003eOutpatient\u003c/span\u003e; \u003cspan\u003eGeneral Medicine\u003c/span\u003e; period: 23/12/2004 8:00:00 AM --\u0026gt; 23/12/2004 8:01:00 AM; date: 24/12/2005 9:43:41 AM; description: Physical; \u003cspan\u003every restricted\u003c/span\u003e\u003c/a\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003ename\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eproductName\u003c/b\u003e: Equilidem 2.5 mg film-coated tablets\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003enamePart\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epart\u003c/b\u003e: Equilidem\u003c/p\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: \u003cspan\u003eINV\u003c/span\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003enamePart\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epart\u003c/b\u003e: 2.5 mg\u003c/p\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: \u003cspan\u003eSTR\u003c/span\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003enamePart\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003epart\u003c/b\u003e: film-coated tablets\u003c/p\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: \u003cspan\u003eFRM\u003c/span\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003ch3\u003eCountryLanguages\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eCountry\u003c/b\u003e\u003c/td\u003e\u003ctd\u003e\u003cb\u003eJurisdiction\u003c/b\u003e\u003c/td\u003e\u003ctd\u003e\u003cb\u003eLanguage\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd\u003e\u003cspan\u003eEU\u003c/span\u003e\u003c/td\u003e\u003ctd\u003e\u003cspan\u003eEU\u003c/span\u003e\u003c/td\u003e\u003ctd\u003e\u003cspan\u003eEN\u003c/span\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/blockquote\u003e\u003ch3\u003eManufacturingBusinessOperations\u003c/h3\u003e\u003ctable\u003e\u003ctr\u003e\u003ctd\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eType\u003c/b\u003e\u003c/td\u003e\u003ctd\u003e\u003cb\u003eEffectiveDate\u003c/b\u003e\u003c/td\u003e\u003ctd\u003e\u003cb\u003eAuthorization\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd\u003e*\u003c/td\u003e\u003ctd/\u003e\u003ctd\u003e2013-03-15 --\u0026gt; (ongoing)\u003c/td\u003e\u003ctd\u003e\u003cspan/\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/div\u003e"},"identifier":[{"system":"http://ema.europa.eu/example/MPID","value":"{mpid}"}],"classification":[{"coding":[{"system":"http://ema.europa.eu/example/WHOAnatomicalTherapeuticChemicalATCClassificationSystem","code":"B01AF02"}]}],"attachedDocument":[{"reference":"DocumentReference/example"}],"masterFile":[{"reference":"DocumentReference/example"}],"name":[{"productName":"Equilidem 2.5 mg film-coated tablets","namePart":[{"part":"Equilidem","type":{"coding":[{"code":"INV"}]}},{"part":"2.5 mg","type":{"coding":[{"code":"STR"}]}},{"part":"film-coated tablets","type":{"coding":[{"code":"FRM"}]}}],"countryLanguage":[{"country":{"coding":[{"system":"http://ema.europa.eu/example/countryCode","code":"EU"}]},"jurisdiction":{"coding":[{"system":"http://ema.europa.eu/example/jurisdictionCode","code":"EU"}]},"language":{"coding":[{"system":"http://ema.europa.eu/example/languageCode","code":"EN"}]}}]}],"manufacturingBusinessOperation":[{"type":{"concept":{"coding":[{"system":"http://ema.europa.eu/example/manufacturingOperationType","code":"Batchrelease"}]}},"effectiveDate":{"start":"2013-03-15"},"authorization":{"identifier":{"system":"http://ema.europa.eu/example/manufacturingAuthorisationReferenceNumber","value":"1324TZ"}}}]}